The Greater Cannabis Company, Inc. (GCAN)
OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
At close: 09:52AM EDT
| Previous close | 0.0007 |
| Open | 0.0007 |
| Bid | 0.0007 x 0 |
| Ask | 0.0008 x 0 |
| Day's range | 0.0007 - 0.0008 |
| 52-week range | 0.0004 - 0.0015 |
| Volume | |
| Avg. volume | 3,094,071 |
| Market cap | 643,711 |
| Beta (5Y monthly) | 1.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company had previously announced the preclinical study as part of its license and research agreement with Shaare Zedek Scientific related
© 2024 Yahoo. All rights reserved.